A Randomized Clinical Trial of a Booster Dose with Low Versus Standard Dose of AZD1222 in Adult After 2 Doses of Inactivated Vaccines

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2022 Mar 28

PMID 35341647

Authors

Sira Nanthapisal

Thanyawee Puthanakit

Peera Jaru-Ampornpan

Rapisa Nantanee

Pimpayao Sodsai

Orawan Himananto

Jiratchaya Sophonphan

Pintip Suchartlikitwong

Narin Hiransuthikul

Pornpimon Angkasekwinai

Auchara Tangsathapornpong

Nattiya Hirankarn

Affiliations

Soon will be listed here.

Abstract

Background: Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed.

Objective: To evaluate immunogenicity and reactogenicity of standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults.

Methods: A double-blinded, randomized, controlled trial of adult, aged 18-59 years, with completion of 2-dose CoronaVac at 21-28 days apart for more than 2 months was conducted. Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly; standard dose (SD, 5x10 viral particles) or low dose (LD, 2.5x10 viral particles). Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio (GMR) at day 14 and 90 between LD and SD arms.

Results: From July-August 2021, 422 adults with median age of 44 (IQR 36-51) years were enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64-95) days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD IgG were 18.1%inhibition (95% CI 16.4-20.0) and 111.5 (105.1-118.3) BAU/ml. GMs of sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95% CI 94.3-97.0) and 1975.1 (1841.7-2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4-92.4) and 938.6 (859.9-1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant and anti-S-RBD IgG in LD compared to SD were 1.00 (95% CI 0.98-1.02) and 0.84 (0.76-0.93) at day 14, and 0.98 (0.94-1.03) and 0.89 (0.79-1.00) at day 90, respectively. LD recipients had significantly lower rate of fever (6.8% vs 25.0%) and myalgia (51.9% vs 70.7%) compared to SD.

Conclusion: Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose AZD1222 booster should be considered especially in resource-constrained settings.

Citing Articles

Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.

do Nascimento T, Nogami P, de Oliveira C, Neto W, da Silva C, Ribeiro A Vaccines (Basel). 2024; 12(7).

PMID: 39066430 PMC: 11281708. DOI: 10.3390/vaccines12070792.

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.

Nantanee R, Jaru-Ampornpan P, Chantasrisawad N, Himananto O, Papakhee S, Sophonphan J Vaccine X. 2023; 15:100367.

PMID: 37601322 PMC: 10432840. DOI: 10.1016/j.jvacx.2023.100367.

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Clemens S, Marchevsky N, Kelly S, Felle S, Eldawi A, Rajasingam R Hum Vaccin Immunother. 2023; 19(2):2233400.

PMID: 37438960 PMC: 10348030. DOI: 10.1080/21645515.2023.2233400.

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination.

Terbsiri V, Putcharoen O, Suwanpimolkul G, Jantarabenjakul W, Wacharapluesadee S, Champa N Vaccine X. 2023; 14:100334.

PMID: 37361052 PMC: 10281697. DOI: 10.1016/j.jvacx.2023.100334.

Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India.

Du Z, Wang L, Bai Y, Feng S, Ramachandran S, Lim W Med. 2023; 4(3):182-190.e3.

PMID: 36827972 PMC: 9922587. DOI: 10.1016/j.medj.2023.02.001.

References

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

Du Z, Wang L, Pandey A, Lim W, Chinazzi M, Pastore Y Piontti A . Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nat Med. 2022; 28(5):934-938. PMC: 9117137. DOI: 10.1038/s41591-022-01736-z. View

Kardani K, Bolhassani A, Shahbazi S . Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2015; 34(4):413-423. DOI: 10.1016/j.vaccine.2015.11.062. View

Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S . Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. Vaccines (Basel). 2021; 9(12). PMC: 8703694. DOI: 10.3390/vaccines9121375. View

Palgen J, Feraoun Y, Dzangue-Tchoupou G, Joly C, Martinon F, Le Grand R . Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game. Front Immunol. 2021; 12:612747. PMC: 7982481. DOI: 10.3389/fimmu.2021.612747. View

Choi A, Koch M, Wu K, Chu L, Ma L, Hill A . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021; 27(11):2025-2031. PMC: 8604720. DOI: 10.1038/s41591-021-01527-y. View

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

Mallapaty S . WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. Nature. 2021; 594(7862):161-162. DOI: 10.1038/d41586-021-01497-8. View

10.

Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T . Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. 2021; 40(3):524-530. PMC: 8639402. DOI: 10.1016/j.vaccine.2021.11.083. View

11.

Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V . Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021; 40(3):269-277. DOI: 10.12932/AP-250721-1197. View

12.

Barros-Martins J, Hammerschmidt S, Cossmann A, Odak I, Stankov M, Ramos G . Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021; 27(9):1525-1529. PMC: 8440184. DOI: 10.1038/s41591-021-01449-9. View

13.

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

14.

Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N . CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021; 21(10):1352-1354. PMC: 8389976. DOI: 10.1016/S1473-3099(21)00568-5. View

15.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

16.

Tiwari A, Negi G, Jaiswal R, Aggarwal G, Yadav N, Kumar V . Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India. ISBT Sci Ser. 2021; 16(4):269-275. PMC: 8447206. DOI: 10.1111/voxs.12644. View

17.

Edara V, Pinsky B, Suthar M, Lai L, Davis-Gardner M, Floyd K . Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med. 2021; 385(7):664-666. PMC: 8279090. DOI: 10.1056/NEJMc2107799. View

18.

Chiu N, Chi H, Tu Y, Huang Y, Tai Y, Weng S . To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev Vaccines. 2021; 20(10):1211-1220. PMC: 8425437. DOI: 10.1080/14760584.2021.1971522. View

19.

Jara A, Undurraga E, Gonzalez C, Paredes F, Fontecilla T, Jara G . Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021; 385(10):875-884. PMC: 8279092. DOI: 10.1056/NEJMoa2107715. View

20.

Ratajczak W, Niedzwiedzka-Rystwej P, Tokarz-Deptula B, Deptula W . Immunological memory cells. Cent Eur J Immunol. 2018; 43(2):194-203. PMC: 6102609. DOI: 10.5114/ceji.2018.77390. View